Tailwinds' Take: two keys to this press release. First, this should provide a steady stream of samples, keeping the timeline intact for developing the diagnostic with ResearchDX and getting it to market in Q3. Secondly, more Key Opinion Leader's...
For the past few years modifying T-Cells to express Chimeric Antigen Receptors, a practice known as “CAR-T”,  has been the hottest space in cancer therapy. Through CAR-T therapy, there have been amazing strides made in saving patients suffering from...
Tailwinds' Take: this group of SAB members includes scientists who are working on Anixa's CAR-T therapy, which is a major endorsement of the product and platform. This is a very distinguished team and includes some of the world's top...
SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at...
Tailwinds' Take: with ANIX ready to file an IND within weeks, this patent helps secure their IP around a very promising potential cure for breast cancer. If the IND is approved, initial safety data will be available from an...
My Take on The Market This was a good week in the market, which was a welcome relief. We had a big bailout announced by the federal government and some estimates of how bad COVID19 could be came down a...
Tailwinds' Take: being able to distinguish men who are disease free could dramatically reduce the number of unnecessary biopsies performed annually, resulting in both fewer painful surgeries for patients and large savings for the medical system. SAN JOSE, Calif., April...
SAN JOSE, Calif., Nov. 28, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued a...
Tailwinds' Take: with two products approaching FDA submissions for clinical trials, ANIX is positioned for significant catalysts and value generation over the next few months. SAN JOSE, Calif., Oct. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company...
Please click on the link below to see the complete transcript from Anixa's Investor Update conference call of December 17th, 2019. ANIXA_12172019 transcript
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.